Immunotherapy plus chemotherapy before surgery for stage III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two immunotherapy drugs plus chemotherapy to shrink lung tumors so they can be removed with surgery. The goal is to give patients with stage III unresectable non-small cell lung cancer a chance at surgery and a better outcome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have stage III non-small cell lung cancer that doctors believe cannot be removed with surgery (called unresectable).
- You must not have had any previous treatment for your lung cancer, such as chemotherapy, radiation, or targeted therapy.
- Your tumor must not have certain gene changes (EGFR mutation or ALK rearrangement) that can be tested.
- You must be able to perform daily activities with little or no help (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines an immunotherapy drug (tislelizumab) with chemotherapy before surgery to try to shrink the tumor and possibly make surgery possible later. The goal is to improve outcomes for people with stage III non-small cell lung cancer that is not removable at diagnosis.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests whether giving a combination of two immunotherapy drugs with chemotherapy before surgery can help shrink stage III lung cancer and improve outcomes. It is for people whose cancer has spread to lymph nodes in the chest but can still be removed with surgery.
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with 2 or 4 cycles of chemotherapy before surgery can help shrink tumors and improve outcomes for people with early-stage (stage II-IIIB) non-small cell lung cancer. The goal is to make surgery more effective and possibly reduce the chance of cancer coming back.
This trial tests a new combination of drugs given before surgery for stage III lung cancer. It aims to shrink the tumor to make surgery more effective and possibly improve your chances of a cure.
Hear when a new NSCLC (Non-small-cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.